Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Gergis, Usama  [Clear All Filters]
2022
Yang Y, Bi X, Gergis M, Yi D, Hsu J, Gergis U. Allogeneic Chimeric Antigen Receptor T Cells for Hematologic Malignancies. Hematol Oncol Stem Cell Ther. 2022;15(3):112-116.
Hsu J, Yang Y, Gergis M, Bi X, Yi D, Gergis U. Chimeric Antigen Receptor T Cell Therapy For Solid Tumors. Hematol Oncol Stem Cell Ther. 2022;15(3):94-99.
Yi D, Gergis M, Elgohary G, Hsu J, Yang Y, Bi X, Gergis U. Chimeric Antigen Receptor T-cell Therapies in Lymphoma Patients with Central Nervous System Involvement. Hematol Oncol Stem Cell Ther. 2022;15(3):66-72.
Bi X, Hsu J, Gergis M, Yang Y, Yi D, Gergis U. Chimeric Antigen Receptor T-cell Therapy for Acute Myeloid Leukemia. Hematol Oncol Stem Cell Ther. 2022;15(3):131-136.
Yi D, Gergis M, Hsu J, Yang Y, Bi X, Aljurf M, Gergis U. Next-Generation Chimeric Antigen Receptor T-cells. Hematol Oncol Stem Cell Ther. 2022;15(3):117-121.
Binder AF, Loos K, Xu A, Peedin AR, Gergis U, Karp JKatz, Wilde L. Optimizing Utilization of Blood Products in the Hematologic Malignancy Clinic: Less Is More. JCO Oncol Pract. 2022:OP2100575.
Grosso D, Leiby B, Wilde L, Carabasi M, Filicko-O'Hara J, O'Hara W, Wagner JL, Mateja G, Alpdogan O, Binder A, et al. A Prospective, Randomized Trial Examining the Use of G-CSF versus No G-CSF in Patients Post-Autologous Transplant. Transplant Cell Ther. 2022.
Alseraihy A, McGrath E, Niederwieser D, Chabannon C, Szer J, Mohty M, Kharfan-Dabaja MA, Orchard K, Schwartz J, Rasheed W, et al. WBMT Special Article on Key Elements in Quality and Accreditation in Hematopoietic Stem Cell Transplantation and Cellular Therapy. Transplant Cell Ther. 2022.
2020
Hsu JW, Shaw BE, Kim S, Logan BR, Sees JA, Confer DL, Pulsipher MA, Shah N, Switzer GE, Abidi MH, et al. Collection of Peripheral Blood Progenitor Cells in One Day is Associated with Decreased Donor Toxicity compared to Two Days in Unrelated Donors. Biol Blood Marrow Transplant. 2020.
Mehta RS, Holtan SG, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel DR, Alousi AM, Pidala J, Abdel-Azim H, et al. Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. J Clin Oncol. 2020:JCO1900396.
Arnold SD, Brazauskas R, He N, Li Y, Hall M, Atsuta Y, Dalal J, Hahn T, Khera N, Bonfim C, et al. The impact of donor type on outcomes and cost of allogeneic hematopoietic cell transplant for pediatric leukemia: a merged CIBMTR and PHIS analysis: Pediatric acute leukemia transplant risks and utilization. Biol Blood Marrow Transplant. 2020.
Seshadri M, Crane GM, Gergis U. Ofatumumab for posttransplant lymphoproliferative disorder. Hematol Oncol Stem Cell Ther. 2020.
Nazha A, Hu Z-H, Wang T, R Lindsley C, Abdel-Azim H, Aljurf M, Bacher U, Bashey A, Cahn J-Y, Cerny J, et al. A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Myelodysplastic Syndromes Patients. Biol Blood Marrow Transplant. 2020.
Zhou Z, Nath R, Cerny J, Wang H-L, Zhang M-J, Abdel-Azim H, Agrawal V, Ahmed G, A Al-Homsi S, Aljurf M, et al. Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. Blood Adv. 2020;4(13):3180-3190.
Im A, Rashidi A, Wang T, Hemmer M, MacMillan ML, Pidala J, Jagasia M, Pavletic S, Majhail NS, Weisdorf D, et al. Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. Biol Blood Marrow Transplant. 2020.

Pages